Top Markets
Coin of the day
MGC Pharmaceuticals Limited MGC Pharmaceuticals Limited

MGC Pharmaceuticals Limited

MXC
Rang in aandelen #39836
MGC Pharmaceuticals Limited, an Australian biopharmaceutical firm established... MGC Pharmaceuticals Limited, an Australian biopharmaceutical firm established in West Perth in 2014, focuses on the worldwide development and distribution of plant-derived medicines. Its product portfolio encompasses both medicinal cannabis solutions and other botanical therapeutics. The company's key investigational treatments include CimetrA, currently in Phase III clinical trials for the symptomatic relief of early-stage COVID-19; CannEpil, a cannabis-based therapy undergoing Phase IIb studies for drug-resistant epilepsy; and CogniCann, which is in Phase II clinical development for alleviating dementia symptoms. Beyond these core candidates, MGC Pharmaceuticals also supplies the ArtemiC range, various other cannabinoid-infused products, and non-pharmaceutical items. Additionally, the company provides expert consulting services, particularly in clinical research. The company was previously named Erin Resources Limited before adopting its current identity, MGC Pharmaceuticals Limited, in December 2015.
Aandeelprijs
$0.27239819
Laatst gesynchroniseerd: 2024-04-29
Marktkapitalisatie
$330.42K
Verandering (1 dag)
0.52%
Verandering (1 jaar)
0.00%
Land
AU
Handel MGC Pharmaceuticals Limited (MXC)

Categorie

P/S-ratio voor MGC Pharmaceuticals Limited (MXC)
P/S-ratio op 2026 TTM: 0
Volgens de meest recente financiële rapporten en aandelenkoers van MGC Pharmaceuticals Limited is de huidige P/S-ratio (TTM) 0. Eind 2026 had het bedrijf een P/S-ratio van 0.
P/S-ratiohistoriek voor MGC Pharmaceuticals Limited van 2026 tot 2026
P/S-ratio aan het einde van elk jaar
Jaar P/S-ratio Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
P/S-ratio voor vergelijkbare bedrijven of concurrenten